Call specialist+30 698 319 9086

Constantine Stratakis, MD, D(Med)Sci, PhD

Co-founder and Director, Astrea Health · Astrea Health

Medical genetics and endocrine-genetics care from a former NIH/NICHD director

Cancer Prevention & ScreeningHormone OptimizationMetabolic Health
Constantine Stratakis, MD, D(Med)Sci, PhD portrait

About

Constantine A. Stratakis, MD, D(Med)Sci, PhD is Astrea Health's co-founder and director. He trained in medicine in Athens, then completed pediatrics, endocrinology, and medical genetics at Georgetown University before a long NIH/NICHD career leading genetics and endocrinology programs. His research record includes 800+ publications, 62,000+ Google Scholar citations, the identification of PRKAR1A in Carney complex, and the disease eponym Carney-Stratakis syndrome. At Astrea, that background anchors the clinic's clinical-genetics and longevity-planning model.

What to Know

Signature approach

Stratakis reads genomic findings through a physician's endocrine and tumor-genetics lens. Whole-exome or targeted-panel results are interpreted against family history, hormone-axis questions, and disease-risk patterns, then translated into prevention, surveillance, counseling, or treatment decisions. The consult is genetics-forward, with longevity planning built from risk signals rather than broad wellness advice.

What sets them apart

  • Rare research depth in a clinic director. 800+ publications, h-index 124, and 62,000+ Google Scholar citations give his Astrea role a substantial genetics-research base.
  • NIH operating scale. He directed NIH/NICHD intramural research programs with roughly 1,100 staff and a $200M annual budget.
  • Named endocrine-genetics contribution. Carney-Stratakis syndrome bears his name, and his work helped define the genetics of Carney complex.

Before You Book

  • Ask for fit. He is best used for complex genetics, endocrine-genetics, hereditary-risk, or precision-medicine questions where his depth changes the interpretation.
  • Coordinate availability. He also holds academic and research roles at IMBB/FORTH and the University of Athens, so direct appointment timing should be confirmed early.
  • Team-based workflow. Counseling, sampling, and follow-up may involve Astrea's broader genetics and lab team even when his clinical oversight shapes the case.

Expertise

Focus areas

Cancer Prevention & ScreeningHormone OptimizationMetabolic Health

Patient types

General Adult LongevityFamilies & Pediatric LongevityPost-Cancer Patients

Credentials

Education

  • MD, Medicine

    University of Athens, School of Medicine (1989)

  • D(Med)Sci, Medical Sciences

    University of Athens

  • Honorary PhD

    University of Liege

  • Honorary PhD

    University of Athens

  • Executive Leadership Program

    University of Maryland School of Public Policy

Residency

  • Pediatrics

    Georgetown University, Washington DC

Fellowship

  • Endocrinology and Medical Genetics

    Georgetown University, Washington DC

Affiliations

Co-Founder

Athens

Thought Leadership

Books

Publications

  • Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation · New England Journal of Medicine, 2014
  • Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations · Proceedings of the National Academy of Sciences, 2011
  • A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia · Nature Genetics, 2006
  • A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues · Cancer Research, 2005

Other specialists at Astrea Health

Directory listings are for informational purposes only. Inclusion does not constitute endorsement. Verify credentials and qualifications independently.